for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AbbVie Inc

ABBV.N

Latest Trade

74.75USD

Change

0.25(+0.34%)

Volume

2,378,380

Today's Range

74.36

 - 

74.98

52 Week Range

62.68

 - 

94.98

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Allergan Shareholders Approve Proposed Acquisition By Abbvie

Oct 14 (Reuters) - Allergan plc <AGN.N>::ALLERGAN SHAREHOLDERS APPROVE PROPOSED ACQUISITION BY ABBVIE.ALLERGAN PLC - PROPOSED ACQUISITION BY ABBVIE IS EXPECTED TO CLOSE IN EARLY 2020.ALLERGAN - MORE THAN 99% OF VOTES CAST AT SPECIAL COURT-ORDERED MEETING & EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS WERE IN FAVOR OF ABBVIE DEAL.

Reata Pharmaceuticals Reacquires Rights From Abbvie To Develop And Commercialize Bardoxolone Methyl, Omaveloxolone, And All Next-Generation Nrf2 Activators

Oct 10 (Reuters) - Reata Pharmaceuticals Inc <RETA.O>::REATA PHARMACEUTICALS REACQUIRES RIGHTS FROM ABBVIE TO DEVELOP AND COMMERCIALIZE BARDOXOLONE METHYL, OMAVELOXOLONE, AND ALL NEXT-GENERATION NRF2 ACTIVATORS.REATA PHARMACEUTICALS INC - ABBVIE WILL RECEIVE A TOTAL OF $330 MILLION IN CASH, PRIMARILY FOR RIGHTS TO BARDOXOLONE.REATA PHARMACEUTICALS INC - REATA WILL MAKE AN UPFRONT PAYMENT OF $75 MILLION IN 2019.REATA PHARMA- ABBVIE WILL RECEIVE LOW SINGLE-DIGIT, TIERED ROYALTIES FROM WORLDWIDE SALES OF OMAVELOXOLONE AND CERTAIN NEXT-GENERATION NRF2 ACTIVATORS.REATA PHARMACEUTICALS - REATA HAS ALSO ENTERED INTO AN AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH OXFORD FINANCE LLC AND SILICON VALLEY BANK.REATA PHARMACEUTICALS INC - ABBVIE WILL NOT RECEIVE ROYALTIES ON BARDOXOLONE.REATA PHARMA - ACTIVELY PREPARING FOR COMMERCIAL LAUNCH OF BARDOXOLONE AND OMAVELOXOLONE IN U.S..REATA PHARMACEUTICALS INC - AMENDED AGREEMENT MAKES $75 MILLION AVAILABLE TO CO UPON POSITIVE, TOPLINE DATA FROM EITHER CARDINAL STUDY OR MOXIE STUDY.REATA PHARMACEUTICALS INC - OVERALL, TERM LOAN FACILITY INCREASED BY $30 MILLION, FROM $125 MILLION TO $155 MILLION.

Abbvie Announces New Data From Its Dermatology Portfolio And Pipeline

Oct 9 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE ANNOUNCES NEW DATA FROM ITS DERMATOLOGY PORTFOLIO AND PIPELINE.ABBVIE ANNOUNCES NEW DATA FROM ITS DERMATOLOGY PORTFOLIO AND PIPELINE AT THE 28TH EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) CONGRESS.ABBVIE - NEW DATA FROM A PHASE 2B INVESTIGATIONAL STUDY EVALUATING TIME TO TREATMENT RESPONSE WITH UPADACITINIB FOR PATIENTS WITH ATOPIC DERMATITIS.ABBVIE-RESULTS FROM LIMMITLESS TRIAL EVALUATING SAFETY,EFFICACY WITH SKYRIZI IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS AT 2.5 YRS TO BE PRESENTED.ABBVIE -SAFETY,EFFICACY DATA UP TO 24 WEEKS TO BE PRESENTED FROM RISANKIZUMAB PHASE 2 INVESTIGATIONAL STUDIES FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS.

Allergan And Abbvie Receive Second Request From Federal Trade Commission On Pending Transaction

Sept 27 (Reuters) - Abbvie Inc <ABBV.N>::ALLERGAN AND ABBVIE RECEIVE SECOND REQUEST FROM FEDERAL TRADE COMMISSION ON PENDING TRANSACTION.ALLERGAN PLC - HAS SCHEDULED TWO SPECIAL SHAREHOLDER MEETINGS ON OCTOBER 14, 2019 TO SEEK APPROVAL OF ITS SHAREHOLDERS FOR ABBVIE DEAL.

Abbvie And Allergan Receive Second Request From FTC On Pending Transaction

Sept 27 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE AND ALLERGAN RECEIVE SECOND REQUEST FROM FEDERAL TRADE COMMISSION ON PENDING TRANSACTION.ABBVIE INC - CO AND ALLERGAN ARE COOPERATING FULLY WITH FTC AND CONTINUE TO EXPECT TO CLOSE TRANSACTION IN EARLY 2020.

FDA Approves Treatment For Adults, Children With All Genotypes Of Hepatitis C And Compensated Cirrhosis

Sept 26 (Reuters) - Abbvie Inc <ABBV.N>::FDA APPROVES TREATMENT FOR ADULTS AND CHILDREN WITH ALL GENOTYPES OF HEPATITIS C AND COMPENSATED CIRRHOSIS THAT SHORTENS DURATION OF TREATMENT TO EIGHT WEEKS.U.S. FOOD AND DRUG ADMINISTRATION - EXPANDED APPROVAL OF MAVYRET (GLECAPREVIR AND PIBRENTASVIR) TABLETS.FDA SAYS GRANTED APPROVAL OF MAVYRET TO ABBVIE INC.

Abbvie Inc Says Offering €750 Million Of Its 0.750% Senior Notes Due 2027 & €650 Million Of Its 1.250% Senior Notes Due 2031

Sept 19 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE INC - OFFERING €750 MILLION OF ITS 0.750% SENIOR NOTES DUE 2027 & €650 MILLION OF ITS 1.250% SENIOR NOTES DUE 2031.

Abbvie Files Preliminary Prospectus For Potential Offering Of Two € Denominated Senior Notes

Sept 16 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE INC - FILES PRELIMINARY PROSPECTUS FOR POTENTIAL OFFERING OF TWO € DENOMINATED SENIOR NOTES - SEC FILING.

Abbvie Sets Quarterly Cash Dividend Of $1.07 Per Share

Sept 6 (Reuters) - Abbvie Inc <ABBV.N>::SETS QUARTERLY CASH DIVIDEND OF $1.07PER SHARE.

Idera Pharma Announces Immuno-Oncology Clinical Research Collaboration With Abbvie

Sept 4 (Reuters) - Idera Pharmaceuticals Inc <IDRA.O>::IDERA PHARMACEUTICALS ANNOUNCES IMMUNO-ONCOLOGY CLINICAL RESEARCH COLLABORATION WITH ABBVIE.IDERA PHARMACEUTICALS INC - ENTERED INTO AN IMMUNO-ONCOLOGY CLINICAL RESEARCH COLLABORATION WITH ABBVIE.IDERA PHARMACEUTICALS INC - PHASE 1B TO DETERMINE SAFETY OF COMBINATIONS OF ABBV-368 PLUS TILSOTOLIMOD IN SUBJECTS WITH RECURRENT OR METASTATIC HNSCC.IDERA PHARMACEUTICALS INC - STUDY WILL TEST THREE SEPARATE TREATMENT ARMS.IDERA PHARMACEUTICALS INC - IDERA WILL PROVIDE CLINICAL TRIAL SUPPLY OF TILSOTOLIMOD TO ABBVIE AND ABBVIE WILL BE RESPONSIBLE FOR CONDUCT OF STUDY.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up